- Vienna '18
- Athens 2019
- ESCRS Player
- On Demand
- ESCRS iLearn
- ESCRS YO's
First Author: J.Rüping GERMANY
Co Author(s): D. Kook E. Vounotrypidis T. Kreutzer A. Kampik E. Messmer K. Eibl
Back to previous
To evaluate safety and short-term efficacy of transepithelial corneal crosslinking (TE-CXL) with riboflavin 0.1% and ultraviolet-A radiation for treatment of progressive keratoconus (Krumeich stage 2 and 3).
Department of Ophthalmology, Ludwig-Maximilians-University, Munich, Germany
7 eyes of 8 patients with a history of progressive keratokonus and thinnest point of pachymetry between 380 and 410 ṁm were included in this study. TE-CXL was performed using riboflavin 0.1% enhanced solution (Ricrolin TE®, Sooft Italia; riboflavin 0.1%, dextrane T500 15%, trometamol and EDTA). The following parameters were evaluated preoperatively and 3 and 6 months postoperatively: CDVA, IOP, biomicroscopical assessment of anterior eye segment, pachymetry and corneal topography (Pentacam®, Oculus GmbH, Wetzlar, Germany).
No ocular complications were observed during and after TE-CXL. At 6 months postoperatively, mean corneal thickness decreased from 407 ṁm to 397 ṁm, mean K-max increased from 61.3 D to 67.6 D, mean corneal astigmatism increased from 6.0 D to 6.2 D and CDVA improved slightly by 0.043 logMAR.
Transepithelial corneal crosslinking with riboflavin 0.1% enhanced solution is a safe procedure without postoperative pain and other complications as seen in epithelium-off standard crosslinking. However, in terms of shape stabilisation and prevention of disease progression, it seems to be less effective than the standard protocoll. Further investigantion is needed to assess long-term efficacy of TE-CXL.